New York, NY – According to filings with the U.S. Securities and Exchange Commission, Spine BioPharma is raising $30,350,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Marc Viscogliosi played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Spine BioPharma
Spine BioPharma is committed to bringing to market innovative non-surgical, non-opiate therapies to treat degenerative spine related diseases. Our pipeline of therapeutic treatments target the clinical benefits of reducing pain, restoring function and slowing or stopping pathological disease progression. Our mission is to improve the lives of millions of individuals suffering every day from degenerative spine diseases by delivering clinically proven, safe, and effective therapies that inhibit pain and inflammation, and restores quality-of-life. We are a team of solutions-oriented spine-disease experts that have dedicated our lives to making a difference for patients. Through partnerships with pharmaceutical companies, brilliant scientists and compassionate clinicians, we have assembled a portfolio of degenerative spine disease-specific therapeutic solutions that represent first-in-class and best-in-class potential treatments for millions of patients. Our therapeutic solutions are backed by solid science and clinical experience. We look forward to bringing them through the regulatory approval processes to create access for millions of patients suffering from debilitating spinal diseases.

To learn more about Spine BioPharma, visit http://www.spinebiopharma.com/

Contact:
Marc Viscogliosi, Chief Executive Officer
212-583-9700
https://www.linkedin.com/in/marc-viscogliosi-750ba6b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved